Glucose homeostasis in statin users—The LIFESTAT study
Background Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) and of type 2 diabetes. However, the underlying mechanisms remain disputed. Methods We investigated whe...
Gespeichert in:
| Veröffentlicht in: | Diabetes/metabolism research and reviews 2019-03, Vol.35 (3), p.e3110-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e3110 |
| container_title | Diabetes/metabolism research and reviews |
| container_volume | 35 |
| creator | Morville, Thomas Dohlmann, Tine Kuhlman, Anja B. Monberg, Tine Torp, Mimmi Hartmann, Bolette Holst, Jens J. Larsen, Steen Helge, Jørn W. Dela, Flemming |
| description | Background
Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) and of type 2 diabetes. However, the underlying mechanisms remain disputed.
Methods
We investigated whether statin induced myalgia is coupled to impaired glucose homeostasis using oral glucose tolerance test (OGTT), intravenous glucose tolerance test (IVGTT), and the hyperinsulinemic euglycemic clamp. We performed a cross‐sectional study of statin users without CVD (primary prevention) stratified into a statin myalgic (M; n = 25) and a non‐myalgic (NM; n = 39) group as well as a control group (C; n = 20) consisting of non‐statin users.
Results
A reduction in the insulin secretion rate during the OGTT was observed in the myalgic group compared with the non‐myalgic group (AUC ISROGTT, C: 1032 (683 ‐ 1500); M: 922 (678 ‐ 1091); NM: 1089 (933 ‐ 1391) pmol·L−1·min (median with 25%‐75% percentiles), but no other measurements indicated impaired β‐cell function. We found no other differences between the three groups for other measurements in the OGTT, IVGTT, and euglycemic clamp. Muscle protein content of GLUT4 and hexokinase II was similar between the three groups.
Conclusions
We conclude that statin users in primary prevention experiencing myalgia do not have impaired glucose homeostasis compared with other statin users or non‐users. We consider this an important aspect in the dialogue between physician and patient regarding statin treatment and adverse effects. |
| doi_str_mv | 10.1002/dmrr.3110 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2159981101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2159981101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3530-db60861d74e1355bcf72d76ec381982543155b927ba0fcd3839da793a290a3ad3</originalsourceid><addsrcrecordid>eNp10MtOAjEUBuDGaATRhS9gSNzoYqCX6W1JEJAEY4LjuulMO2HIDIMtE8POh_AJfRKLIAsTV-ek_fKn_QG4RrCHIMR9UznXIwjBE9BGFMOIUwZPjzvFLXDh_RJCSGIWn4MWgRRxyUUbiEnZZLW33UVd2dpvtC98t1h1w7YJo_HW-a-Pz2Rhu7PpePSSDJJw15jtJTjLdent1WF2wOt4lAwfo9nzZDoczKKMUAIjkzIoGDI8tohQmmY5x4YzmxGBpMA0JiicSsxTDfPMEEGk0VwSjSXURBvSAXf73LWr3xrrN6oqfGbLUq9s3XiFEZVShL-jQG__0GXduFV4XVBCQMYkYUHd71Xmau-dzdXaFZV2W4Wg2tWpdnWqXZ3B3hwSm7Sy5ih_-wugvwfvRWm3_yeph6f5_CfyG5skfWM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2188066936</pqid></control><display><type>article</type><title>Glucose homeostasis in statin users—The LIFESTAT study</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Morville, Thomas ; Dohlmann, Tine ; Kuhlman, Anja B. ; Monberg, Tine ; Torp, Mimmi ; Hartmann, Bolette ; Holst, Jens J. ; Larsen, Steen ; Helge, Jørn W. ; Dela, Flemming</creator><creatorcontrib>Morville, Thomas ; Dohlmann, Tine ; Kuhlman, Anja B. ; Monberg, Tine ; Torp, Mimmi ; Hartmann, Bolette ; Holst, Jens J. ; Larsen, Steen ; Helge, Jørn W. ; Dela, Flemming</creatorcontrib><description>Background
Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) and of type 2 diabetes. However, the underlying mechanisms remain disputed.
Methods
We investigated whether statin induced myalgia is coupled to impaired glucose homeostasis using oral glucose tolerance test (OGTT), intravenous glucose tolerance test (IVGTT), and the hyperinsulinemic euglycemic clamp. We performed a cross‐sectional study of statin users without CVD (primary prevention) stratified into a statin myalgic (M; n = 25) and a non‐myalgic (NM; n = 39) group as well as a control group (C; n = 20) consisting of non‐statin users.
Results
A reduction in the insulin secretion rate during the OGTT was observed in the myalgic group compared with the non‐myalgic group (AUC ISROGTT, C: 1032 (683 ‐ 1500); M: 922 (678 ‐ 1091); NM: 1089 (933 ‐ 1391) pmol·L−1·min (median with 25%‐75% percentiles), but no other measurements indicated impaired β‐cell function. We found no other differences between the three groups for other measurements in the OGTT, IVGTT, and euglycemic clamp. Muscle protein content of GLUT4 and hexokinase II was similar between the three groups.
Conclusions
We conclude that statin users in primary prevention experiencing myalgia do not have impaired glucose homeostasis compared with other statin users or non‐users. We consider this an important aspect in the dialogue between physician and patient regarding statin treatment and adverse effects.</description><identifier>ISSN: 1520-7552</identifier><identifier>EISSN: 1520-7560</identifier><identifier>DOI: 10.1002/dmrr.3110</identifier><identifier>PMID: 30517978</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Cardiovascular diseases ; Cardiovascular Diseases - prevention & control ; Cholesterol ; Cross-Sectional Studies ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Female ; Follow-Up Studies ; Glucose ; Glucose Intolerance - drug therapy ; Glucose tolerance ; Glucose Tolerance Test ; Hexokinase ; Homeostasis ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Insulin ; Insulin Resistance ; Insulin secretion ; insulin sensitivity ; Intravenous administration ; Male ; Middle Aged ; Myalgia ; Pain ; Prognosis ; Secretion ; Statins</subject><ispartof>Diabetes/metabolism research and reviews, 2019-03, Vol.35 (3), p.e3110-n/a</ispartof><rights>2018 John Wiley & Sons, Ltd.</rights><rights>2019 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3530-db60861d74e1355bcf72d76ec381982543155b927ba0fcd3839da793a290a3ad3</citedby><cites>FETCH-LOGICAL-c3530-db60861d74e1355bcf72d76ec381982543155b927ba0fcd3839da793a290a3ad3</cites><orcidid>0000-0002-9039-2591</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fdmrr.3110$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fdmrr.3110$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30517978$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morville, Thomas</creatorcontrib><creatorcontrib>Dohlmann, Tine</creatorcontrib><creatorcontrib>Kuhlman, Anja B.</creatorcontrib><creatorcontrib>Monberg, Tine</creatorcontrib><creatorcontrib>Torp, Mimmi</creatorcontrib><creatorcontrib>Hartmann, Bolette</creatorcontrib><creatorcontrib>Holst, Jens J.</creatorcontrib><creatorcontrib>Larsen, Steen</creatorcontrib><creatorcontrib>Helge, Jørn W.</creatorcontrib><creatorcontrib>Dela, Flemming</creatorcontrib><title>Glucose homeostasis in statin users—The LIFESTAT study</title><title>Diabetes/metabolism research and reviews</title><addtitle>Diabetes Metab Res Rev</addtitle><description>Background
Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) and of type 2 diabetes. However, the underlying mechanisms remain disputed.
Methods
We investigated whether statin induced myalgia is coupled to impaired glucose homeostasis using oral glucose tolerance test (OGTT), intravenous glucose tolerance test (IVGTT), and the hyperinsulinemic euglycemic clamp. We performed a cross‐sectional study of statin users without CVD (primary prevention) stratified into a statin myalgic (M; n = 25) and a non‐myalgic (NM; n = 39) group as well as a control group (C; n = 20) consisting of non‐statin users.
Results
A reduction in the insulin secretion rate during the OGTT was observed in the myalgic group compared with the non‐myalgic group (AUC ISROGTT, C: 1032 (683 ‐ 1500); M: 922 (678 ‐ 1091); NM: 1089 (933 ‐ 1391) pmol·L−1·min (median with 25%‐75% percentiles), but no other measurements indicated impaired β‐cell function. We found no other differences between the three groups for other measurements in the OGTT, IVGTT, and euglycemic clamp. Muscle protein content of GLUT4 and hexokinase II was similar between the three groups.
Conclusions
We conclude that statin users in primary prevention experiencing myalgia do not have impaired glucose homeostasis compared with other statin users or non‐users. We consider this an important aspect in the dialogue between physician and patient regarding statin treatment and adverse effects.</description><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cholesterol</subject><subject>Cross-Sectional Studies</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glucose</subject><subject>Glucose Intolerance - drug therapy</subject><subject>Glucose tolerance</subject><subject>Glucose Tolerance Test</subject><subject>Hexokinase</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Insulin</subject><subject>Insulin Resistance</subject><subject>Insulin secretion</subject><subject>insulin sensitivity</subject><subject>Intravenous administration</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myalgia</subject><subject>Pain</subject><subject>Prognosis</subject><subject>Secretion</subject><subject>Statins</subject><issn>1520-7552</issn><issn>1520-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MtOAjEUBuDGaATRhS9gSNzoYqCX6W1JEJAEY4LjuulMO2HIDIMtE8POh_AJfRKLIAsTV-ek_fKn_QG4RrCHIMR9UznXIwjBE9BGFMOIUwZPjzvFLXDh_RJCSGIWn4MWgRRxyUUbiEnZZLW33UVd2dpvtC98t1h1w7YJo_HW-a-Pz2Rhu7PpePSSDJJw15jtJTjLdent1WF2wOt4lAwfo9nzZDoczKKMUAIjkzIoGDI8tohQmmY5x4YzmxGBpMA0JiicSsxTDfPMEEGk0VwSjSXURBvSAXf73LWr3xrrN6oqfGbLUq9s3XiFEZVShL-jQG__0GXduFV4XVBCQMYkYUHd71Xmau-dzdXaFZV2W4Wg2tWpdnWqXZ3B3hwSm7Sy5ih_-wugvwfvRWm3_yeph6f5_CfyG5skfWM</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Morville, Thomas</creator><creator>Dohlmann, Tine</creator><creator>Kuhlman, Anja B.</creator><creator>Monberg, Tine</creator><creator>Torp, Mimmi</creator><creator>Hartmann, Bolette</creator><creator>Holst, Jens J.</creator><creator>Larsen, Steen</creator><creator>Helge, Jørn W.</creator><creator>Dela, Flemming</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9039-2591</orcidid></search><sort><creationdate>201903</creationdate><title>Glucose homeostasis in statin users—The LIFESTAT study</title><author>Morville, Thomas ; Dohlmann, Tine ; Kuhlman, Anja B. ; Monberg, Tine ; Torp, Mimmi ; Hartmann, Bolette ; Holst, Jens J. ; Larsen, Steen ; Helge, Jørn W. ; Dela, Flemming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3530-db60861d74e1355bcf72d76ec381982543155b927ba0fcd3839da793a290a3ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cholesterol</topic><topic>Cross-Sectional Studies</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glucose</topic><topic>Glucose Intolerance - drug therapy</topic><topic>Glucose tolerance</topic><topic>Glucose Tolerance Test</topic><topic>Hexokinase</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Insulin</topic><topic>Insulin Resistance</topic><topic>Insulin secretion</topic><topic>insulin sensitivity</topic><topic>Intravenous administration</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myalgia</topic><topic>Pain</topic><topic>Prognosis</topic><topic>Secretion</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morville, Thomas</creatorcontrib><creatorcontrib>Dohlmann, Tine</creatorcontrib><creatorcontrib>Kuhlman, Anja B.</creatorcontrib><creatorcontrib>Monberg, Tine</creatorcontrib><creatorcontrib>Torp, Mimmi</creatorcontrib><creatorcontrib>Hartmann, Bolette</creatorcontrib><creatorcontrib>Holst, Jens J.</creatorcontrib><creatorcontrib>Larsen, Steen</creatorcontrib><creatorcontrib>Helge, Jørn W.</creatorcontrib><creatorcontrib>Dela, Flemming</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes/metabolism research and reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morville, Thomas</au><au>Dohlmann, Tine</au><au>Kuhlman, Anja B.</au><au>Monberg, Tine</au><au>Torp, Mimmi</au><au>Hartmann, Bolette</au><au>Holst, Jens J.</au><au>Larsen, Steen</au><au>Helge, Jørn W.</au><au>Dela, Flemming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glucose homeostasis in statin users—The LIFESTAT study</atitle><jtitle>Diabetes/metabolism research and reviews</jtitle><addtitle>Diabetes Metab Res Rev</addtitle><date>2019-03</date><risdate>2019</risdate><volume>35</volume><issue>3</issue><spage>e3110</spage><epage>n/a</epage><pages>e3110-n/a</pages><issn>1520-7552</issn><eissn>1520-7560</eissn><abstract>Background
Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) and of type 2 diabetes. However, the underlying mechanisms remain disputed.
Methods
We investigated whether statin induced myalgia is coupled to impaired glucose homeostasis using oral glucose tolerance test (OGTT), intravenous glucose tolerance test (IVGTT), and the hyperinsulinemic euglycemic clamp. We performed a cross‐sectional study of statin users without CVD (primary prevention) stratified into a statin myalgic (M; n = 25) and a non‐myalgic (NM; n = 39) group as well as a control group (C; n = 20) consisting of non‐statin users.
Results
A reduction in the insulin secretion rate during the OGTT was observed in the myalgic group compared with the non‐myalgic group (AUC ISROGTT, C: 1032 (683 ‐ 1500); M: 922 (678 ‐ 1091); NM: 1089 (933 ‐ 1391) pmol·L−1·min (median with 25%‐75% percentiles), but no other measurements indicated impaired β‐cell function. We found no other differences between the three groups for other measurements in the OGTT, IVGTT, and euglycemic clamp. Muscle protein content of GLUT4 and hexokinase II was similar between the three groups.
Conclusions
We conclude that statin users in primary prevention experiencing myalgia do not have impaired glucose homeostasis compared with other statin users or non‐users. We consider this an important aspect in the dialogue between physician and patient regarding statin treatment and adverse effects.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30517978</pmid><doi>10.1002/dmrr.3110</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9039-2591</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-7552 |
| ispartof | Diabetes/metabolism research and reviews, 2019-03, Vol.35 (3), p.e3110-n/a |
| issn | 1520-7552 1520-7560 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2159981101 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Cardiovascular diseases Cardiovascular Diseases - prevention & control Cholesterol Cross-Sectional Studies Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Female Follow-Up Studies Glucose Glucose Intolerance - drug therapy Glucose tolerance Glucose Tolerance Test Hexokinase Homeostasis Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Insulin Insulin Resistance Insulin secretion insulin sensitivity Intravenous administration Male Middle Aged Myalgia Pain Prognosis Secretion Statins |
| title | Glucose homeostasis in statin users—The LIFESTAT study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T04%3A41%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glucose%20homeostasis%20in%20statin%20users%E2%80%94The%20LIFESTAT%20study&rft.jtitle=Diabetes/metabolism%20research%20and%20reviews&rft.au=Morville,%20Thomas&rft.date=2019-03&rft.volume=35&rft.issue=3&rft.spage=e3110&rft.epage=n/a&rft.pages=e3110-n/a&rft.issn=1520-7552&rft.eissn=1520-7560&rft_id=info:doi/10.1002/dmrr.3110&rft_dat=%3Cproquest_cross%3E2159981101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2188066936&rft_id=info:pmid/30517978&rfr_iscdi=true |